Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
Thu, 27 Jun 2024
2024年6月27日
MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD), announced today the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap.
賓夕法尼亞州馬爾弗恩，2024年6月27日（全球新聞社）-通過IBN發佈-Annovis Bio公司。（紐交所：ANVS（“安諾維斯”或“公司”）是一家後期臨床藥物平台公司，致力於開發改變神經退行性疾病，如阿爾茨海默病（AD）和帕金森病（PD）的轉化療法。今天宣佈，提交了一項關於製造新的buntanetap固體形式的專利申請。
This patent encompasses the methods for manufacturing the new crystalline form of buntanetap (CAS# 3032752-92-1), which has demonstrated exceptional stability and efficacy. The patent also covers the entire synthesis process, from basic starting materials to finished (>99.9% pure) GMP product, suitable for manufacturing scale at ton quantities. The new process offers significant benefits, including excellent yields, the avoidance of potentially genotoxic reagents, and a purer product. The CMC protocol was submitted to the FDA and will be discussed in July, with the goal of continuing development of our drug and filing the NDA with the new crystal form.
該專利涵蓋的是製造新的結晶態buntanetap的方法（CAS＃3032752-92-1），它表現出卓越的穩定性和療效。該專利還涵蓋了從基礎起始原料到製造規模的壓噸級的成品（>99.9％純）的整個合成過程。新工藝提供了顯着的優勢，包括卓越的產量，避免可能具有遺傳毒性的試劑以及更純淨的產品。該CMC方案已提交FDA，將在7月討論，並旨在繼續開發我們的藥物並使用新的晶體形態提交NDA。
"As we continue to advance our pipeline, securing our manufacturing rights for new forms of buntanetap is vital. This ensures we maintain control over the production process, protect our intellectual property, and continue our mission to deliver novel therapeutics for patients suffering from neurodegenerative disorders," said Michael Christie, Ph.D., Vice President of Process Chemistry at Annovis.
“隨着我們繼續推進管線，確保獲得buntanetap新形式的製造權至關重要。這確保我們控制生產過程，保護知識產權，並繼續推動向神經退行性疾病患者提供新型治療法的使命，”安諾維斯過程化學副總裁邁克爾·克里斯蒂博士說。
About Buntanetap
Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic transmission, axonal transport, and reduces neuroinflammation. Dysregulation of these pathways has been shown to cause nerve cell degeneration and ultimately nerve cell death. By targeting these pathways, buntanetap has the potential to reverse neurodegeneration in Alzheimer's, Parkinson's, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients.
關於 Buntanetap
Buntanetap（前身爲Posiphen或ANVS401）通過抑制多種神經毒性蛋白，包括澱粉樣蛋白，tau蛋白，α-突觸核蛋白和TDP43，來靶向神經退行性疾病。這提高了突觸傳輸，軸突運輸，並減少了神經炎症。這些通路的失調已被證明會導致神經元退行性和最終神經元死亡。通過針對這些通路，buntanetap有望逆轉神經退化，在阿爾茨海默病，帕金森病和其他神經退行性疾病中，從而旨在恢復大腦功能並提高患者的生活質量。
About Annovis Bio, Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company's innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Annovis Bio，Inc.
總部位於賓夕法尼亞州馬爾文的Annovis Bio Inc.致力於解決AD和PD等疾病中的神經退行問題。該公司的創新方法針對多種神經毒素蛋白，旨在恢復大腦功能並提高患者的生活質量。www.annovisbio.com和我們一起LinkedIn, YouTube和grupo aval股票
和價值sa.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.Annovisbio.com/email-alerts.
鼓勵感興趣的投資者和股東通過註冊電子郵件提醒來註冊以獲取新聞發佈和行業更新。https://www.Annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
前瞻性聲明
早期AD患者的有效性
Contacts
Annovis Bio, Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
聯繫方式
Annovis Bio, Inc.
101 Lindenwood Drive
225套房
馬爾文，PA 19355
www.annovisbio.com
Investor Contact
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
IR@annovisbio.com
Investor Website
投資者聯繫方式
Scott McGowan
InvestorBrandNetwork（IBN）
電話：310.299.1717
IR@annovisbio.com
投資者網站
Source: Annovis Bio, Inc.
消息來源：annovis bio，inc.
譯文內容由第三人軟體翻譯。